A purple and pink letter v on a white background.
May 28, 2024

Venus Concept Announces $35 million Debt-to-Equity Exchange Transaction

Substantial Reduction of Existing Debt by Madryn Asset Management to Support Restructuring Efforts and Compliance with NASDAQ Listing Requirements

TORONTO, May 28, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that, on May 24, 2024, the Company exchanged $35.0 million of its senior debt held by affiliates of Madryn Asset Management, LP (“Madryn”) for 576,986 shares of newly-created Series Y preferred stock. Each share of Series Y preferred stock is convertible into common stock on a 1-for-100 basis at the option of the holder at any time, or automatically upon the Company’s completion of a $30.0 million common equity raise, subject to certain other conditions.


The debt-to-equity exchange represents a significant reduction in the Company’s debt balance, which was $76.7 million as of March 31, 2024. Following the transaction, the Company’s debt balance is approximately $45.4 million.


This transaction was structured to enable the Company to regain compliance with Nasdaq’s minimum stockholders’ equity listing standard. While the Company believes it now has stockholders’ equity in excess of the listing standard, the transaction remains subject to review and final determination by Nasdaq.


“Today represents the completion of another significant milestone in our on-going restructuring efforts towards both streamlining the capital structure of the business as well as our plan to achieve compliance with the Nasdaq minimum equity standard,” said Rajiv De Silva, Chief Executive Officer of Venus Concept. “We are pleased to have the continued long-term support of Madryn. This transaction further strengthens the financing health of the Company and advances our plan towards achieving cash flow breakeven in 2025 and sustainable, long-term profitability, and we believe it will also allow us to maintain our public listing.”


“Our exchange of debt into equity reflects our continued belief in Venus’ market leading position in the aesthetics industry,” said Avinash Amin, MD, Managing Partner at Madryn Asset Management, LP. “We look forward to working with the Company as it continues to execute on its growth plan.”


Cautionary Statement Regarding Forward-Looking Statements


This communication contains “forward-looking statements” statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any statements contained herein that are not of historical facts may be deemed to be forward-looking statements. In some cases, you can identify these statements by words such as such as “anticipates,” “believes,” “plans,” “expects,” “projects,” “future,” “intends,” “may,” “should,” “could,” “estimates,” “predicts,” “potential,” and other similar expressions that are predictions of or indicate future events and future trends. These forward-looking statements include, but are not limited to, statements regarding whether the debt-to-equity exchange will serve to bring the Company into compliance with the minimum equity standard. These forward-looking statements are based on current expectations, estimates, and projections about our business and the industry in which we operate, as well as management's beliefs and assumptions, and are not guarantees of future performance or developments and involve known and unknown risks, uncertainties, and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this communication may turn out to be inaccurate. Factors that could materially affect our business operations and financial performance and condition include, but are not limited to, those risks and uncertainties described under Part I Item 1A—“Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and under Part II Item 1A—“Risk Factors” in our subsequently-filed Quarterly Reports on Form 10-Q. Readers are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on the forward-looking statements. The forward-looking statements are based on information available to us as of the date of this communication. Unless required by law, we do not intend to publicly update or revise any forward-looking statements to reflect new information or future events or otherwise.


About Venus Concept


Venus Concept is an innovative global medical aesthetic technology leader with a broad product portfolio of minimally invasive and non-invasive medical aesthetic and hair restoration technologies and reaches over 60 countries and 12 direct markets. Venus Concept's product portfolio consists of aesthetic device platforms, including Venus Versa, Venus Versa PRO, Venus Legacy, Venus Velocity, Venus Viva, Venus Glow, Venus Bliss, Venus Bliss MAX, Venus Epileve, Venus Viva MD and AI.ME. Venus Concept's hair restoration systems include NeoGraft® and the ARTAS iX® Robotic Hair Restoration system. Venus Concept has been backed by leading healthcare industry growth equity investors including EW Healthcare Partners (formerly Essex Woodlands), HealthQuest Capital, Longitude Capital Management, Aperture Venture Partners, and Masters Special Situations.


Investor Relations Contact:

ICR Westwicke on behalf of Venus Concept:

Mike Piccinino, CFA

VenusConceptIR@westwicke.com


Source: Venus Concept Inc.

September 9, 2026
TORONTO, September 9 th , 2026 (GLOBE NEWSWIRE) – Venus Concept Inc. (“Venus Concept” or the “Company”), a global medical aesthetic technology leader, today announced the appointment of Brad Oliver as Chief Executive Officer, effective as of September 7, 2026. He succeeds Rajiv De Silva, who will assume the role of Special Advisor to support a seamless leadership transition. The Board believes that Brad’s commercial leadership experience, strategic vision, and industry expertise position the Company well for its next phase of growth and value creation. Brad brings more than 20 years of leadership experience in the aesthetic industry, most recently as President & General Manager – Americas at Lumenis, and has a proven track record of driving growth globally, operational excellence, and innovation. "I am honored to be appointed Chief Executive Officer of Venus Concept and grateful for the confidence the Board has placed in me,” said Mr. Oliver. “The Company has established a strong foundation under Rajiv's leadership, and I look forward to working closely with him during the transition. Together with our employees, customers, and partners, we will remain focused on disciplined commercial execution, product innovation, profitable growth, and creating long-term value for our customers, employees, and shareholders.” “It has been a pleasure to lead Venus through a transformational time in the organization’s journey,” said Mr. De Silva. “I am grateful for the opportunity to work together with the leadership team, the Board and our partners to grow the business. We have transformed the commercial, operational and financial capabilities of the organization and built a strong foundation for the future. I remain highly confident in the Company’s strategy, pipeline and long-term growth opportunities. I look forward to supporting a smooth transition and watching Venus continue its transformation under Brad’s new leadership.” The Board expresses its gratitude to Rajiv for his leadership and ongoing commitment to the Company. As Special Advisor, Rajiv will work closely with Brad during the transition period to ensure continuity across strategic, operational, and customer-facing initiatives. “On behalf of the Board, I would like to thank Rajiv for his leadership and contributions to the Company and for his support during this transition to ensure a seamless handoff of leadership responsibilities,” said Avinash Amin, M.D., Managing Partner of Madryn Asset Management and Chairman of the Board. “The Board looks forward to Brad’s new leadership of the organization and is confident that his expertise will accelerate commercial efforts globally and the execution of its strategic priorities as the company progresses towards continuing to establish a leadership position in the Medical Device Aesthetics industry.” The leadership transition is not expected to impact the Company’s strategic priorities, customer relationships, employee commitments, or ongoing business operations. Venus Concept remains focused on delivering innovative solutions to its customers, expanding market opportunities, and driving sustainable long-term growth. About Venus Concept Venus Concept is an innovative global medical aesthetic technology leader with a broad product portfolio of minimally invasive and non-invasive medical aesthetic and hair restoration technologies and reaches over 60 countries and 9 direct markets. Venus Concept's product portfolio consists of aesthetic device platforms, including Venus NOVA, Venus Versa, Venus Versa PRO, Venus Bliss, Venus Bliss MAX, Venus Viva, Venus Viva MD, Venus Legacy, Venus Velocity, Venus Epileve and AI.ME. Venus Concept's hair restoration systems include NeoGraft ® and the ARTAS iX ® Robotic Hair Restoration system. Venus Concept is backed by Madryn Asset Management, a leading healthcare investment firm that provides capital to innovative growth-stage healthcare companies offering unique and transformative products and technologies. View Full Article Investor Relations Contact : Damian Yeung, CPA investorrelations@venus.ai
Purple gradient branding graphic for Doublo × Venus Signature Edition
July 28, 2026
TORONTO, July 28, 2026 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”), a global medical aesthetic technology leader, today announced it has entered into an exclusive distribution agreement with HIRONIC Co. Ltd. (“HIRONIC”), a KOSDAQ listed South Korean company specializing in medical aesthetic devices, pursuant to which the Company acquires the exclusive right to distribute HIRONIC’s Doublo 2.0 device in the United States and Canada. The “New Doublo 2.0” is a synergistic, multi-energy-based medical device platform for the face and body, equipped with two separate handpieces that enables clinics to offer customer Cold Plasma and RF microneedling treatments. The device has received 510(k) certification from the U.S. Food and Drug Administration, and the Company intends to make it available to customers in the United States during 2H 2026. Venus Concept will support future regulatory approval efforts in Canada for the device and any additional handpiece technologies for both regions. “HIRONIC is a global leader in developing innovative medical aesthetic technologies and we are excited for the new partnership, starting with the Doublo x Venus Signature Edition,” said Rajiv De Silva, Chief Executive Officer of Venus Concept. “With this device, we look forward to offering our customers an innovative, exclusive Cold Plasma and RF Microneedling platform. By combining these complementary technologies, the platform delivers synergistic effects from the epidermis to the dermis, enabling comprehensive skin rejuvenation by addressing multiple skin concerns and enhancing overall skin revitalization. The Doublo also complements our existing portfolio by enhancing the range of treatment modalities for a customizable treatment plan to address each patient’s skin needs. We aim to expand our partnership in the future to bring to our customers additional new and novel technologies from HIRONIC, once regulatory approvals have been obtained.” About Venus Concept Venus Concept is an innovative global medical aesthetic technology leader with a broad product portfolio of minimally invasive and non-invasive medical aesthetic and hair restoration technologies and reaches over 60 countries and 9 direct markets. Venus Concept's product portfolio consists of aesthetic device platforms, including Venus NOVA, Venus Versa, Venus Versa PRO, Venus Bliss, Venus Bliss MAX, Venus Viva, Venus Viva MD, Venus Legacy, Venus Velocity, Venus Epileve and AI.ME. Venus Concept's hair restoration systems include NeoGraft® and the ARTAS iX® Robotic Hair Restoration system. Venus Concept is backed by Madryn Asset Management, a leading healthcare investment firm that provides capital to innovative growth-stage healthcare companies offering unique and transformative products and technologies. Investor Relations Contact: Damian Yeung, CPA investorrelations@venus.ai View Full Article
May 22, 2026
Skin Cancer Awareness Month highlights prevention and early detection. Learn how dermatologists support care with advanced tools and treatments.